TAK Takeda Pharmaceutical
- 13.420
- -0.030-0.22%
- 13.260
- -0.160-1.19%
Takeda Pharmaceutical News
6-K: The 148th Interim Period Business Report
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Takeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees
6-K: Closure of Notes Sale Pursuant
6-K: Results of the Exercise of Voting Rights of the 148th Ordinary General Meeting of Shareholders
6-K: Takeda Announces New Assignments of Directors
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Takeda Pharmaceutical | 6-K: Notice Regarding Issuance of JPY Hybrid Bonds
Takeda Pharmaceutical | 6-K: Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Takeda Pharmaceutical | 6-K: Takeda intends to rapidly initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024
Takeda Pharmaceutical | 6-K: Takeda Announces Chief Financial Officer Succession
No Data
